The complaint centers on claims that Regencell issued materially false statements that obscured the company's susceptibility to volatile market conditions. According to the filing, these omissions exposed investors to significant financial risk and invited heightened regulatory scrutiny. The lawsuit suggests that the company’s public disclosures failed to account for the potential for severe legal, monetary, and reputational harm that followed these market fluctuations.
Regencell Bioscience Faces Investor Lawsuit Over Alleged Stock Volatility
Investors who purchased Regencell Bioscience Holdings Limited shares between October 28, 2024, and October 31, 2025, have until June 23, 2026, to file for lead plaintiff status. The Gross Law Firm has initiated a class action, alleging that the company misled shareholders regarding its vulnerability to market manipulation.
Shareholders who participated in the stock during this period are eligible to join the class action. Registration with The Gross Law Firm enrolls participants in portfolio monitoring software to track the progress of the litigation. Participation involves no direct cost or obligation for the investor, and seeking lead plaintiff status is not a prerequisite for recovering potential losses. The deadline to act is June 23, 2026.
Comments (0)
No comments yet. Be the first!